


## Mustafa Tai, MD of PsychPlus Interviewed on MNDA for Anxiety and Depression

## U.S. approval for psychedelic drug MDMA nears after success in clinic



Recognizing that this could be a turning point in mental health research, Mustafa Tai, psychiatrist and medical director at U.S.-based mental healthcare provider PsychPlus said: "This could encourage other countries to take a hard look at legalizing these types of medications as well."

By the end of the study, 86.5% of the people in the MDMA-assisted therapy group achieved a meaningful improvement in the severity of their PTSD symptoms. Moreover, over 71% of the people in the MDMA-assisted therapy group had a reduction in symptoms, to the extent that they no longer qualified for a PTSD diagnosis, compared to nearly 48% of people in the placebo group.

"The outcomes showed that using MDMA positively affected functional impairment including in participants' personal and professional lives," said Tai. "Amazingly, the outcomes showed that over 85% of those that took MDMA, showed clinically significant improvement. Since PTSD is notoriously hard to treat, these results are very positive."